Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intra-Cellular Therapies Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 4, 2016 7:00 AM EDTNEW YORK, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the quarter ended June 30, 2016, and provided a corporate update.
Second Quarter 2016 Financial Results
Intra-Cellular Therapies (the Company or ITCI) reported a net loss of $30.8 million, or $0.71 per share (basic and diluted), for the second quarter of 2016 compared to a net loss of $21.5 million, or $0.61 per share (basic and diluted), for the second quarter of 2015.
... More